Skip to main content

Table 1 Sociodemographic and clinical characteristics of patients

From: Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic hypercapnic respiratory failure: a randomized trial

 Patients treated with AVAPS
(N = 20)
Control group
(N = 20)
Age, years65.8 ± 9.865.4 ± 8.4
Sex: Male n%)12 (60%)10 (50%)
Body mass index (BMI)24.8 ± 8.425.4 ± 7.9
Smoking
• Never1(5%)0(0%)
• Ex-smoker5(25%)6 (30%)
• Current smoker14 (70%)14(70%)
Years since COPD diagnosis9.5 ± 7.49.7 ± 7.9
FEV1, L0.60 ± 0.160.59 ± 0.21
FVC, L2.19 ± 0.551.90 ± 0.50
Underlying disease
 Diabetes7(35%)5(25%)
 Hypertension6 (30%)8(40%)
 Dyslipidemia3 (15%)4(20%)
 Chronic kidney disease1 (5%)2 (10%)
 Coronary artery disease4 (20%)3(15%)
  1. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity